5.32
-0.04 (-0.75%)
| Previous Close | 5.36 |
| Open | 5.41 |
| Volume | 2,113,926 |
| Avg. Volume (3M) | 3,571,357 |
| Market Cap | 3,250,125,824 |
| Price / Sales | 26.22 |
| Price / Book | 2.84 |
| 52 Weeks Range | |
| Earnings Date | 21 Aug 2025 - 25 Aug 2025 |
| Operating Margin (TTM) | -549.59% |
| Diluted EPS (TTM) | -0.560 |
| Quarterly Revenue Growth (YOY) | -15.60% |
| Total Debt/Equity (MRQ) | 29.32% |
| Current Ratio (MRQ) | 6.53 |
| Operating Cash Flow (TTM) | -321.96 M |
| Levered Free Cash Flow (TTM) | -310.27 M |
| Return on Assets (TTM) | -15.39% |
| Return on Equity (TTM) | -31.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (HK) | Mixed | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | ANTENGENE-B | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ANTENGENE-B | 3 B | - | - | 2.84 |
| CSTONE PHARMA-B | 14 B | - | - | 27.87 |
| CKLIFE SCIENCES | 7 B | - | - | 1.88 |
| VIVA BIOTECH | 4 B | - | 28.57 | 0.940 |
| SINOMAB BIO-B | 2 B | - | - | 4.23 |
| IMMUNOTECH-B | 2 B | - | - | 20.15 |
|
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 35.63% |
| % Held by Institutions | 24.97% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |